Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Yeast

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    70 result(s) found for: Yeast. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2021-000333-13 Sponsor Protocol Number: APHP200046 Start Date*: Information not available in EudraCT
    Sponsor Name:APHP DRCI
    Full Title: Efficacy of the nonavalent HPV vaccine in the treatment of difficult-to-treat palmo-plantar warts
    Medical condition: Vaccination by nonavalent vaccine against HPV could lead to a complete resolution of difficult-to-treat palmo-plantar warts in patients of more than 15 years and 3 months of age
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003591-13 Sponsor Protocol Number: V503-076 Start Date*: 2024-05-06
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Conco...
    Medical condition: Papilloma viral infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2018-000407-16 Sponsor Protocol Number: PI2018_843_0007 Start Date*: 2018-12-05
    Sponsor Name:CHU Amiens-Picardie
    Full Title: Prospective multicenter randomized double-blind study comparing caspofungin to placebo for the treatment of ICU yeast intra-abdominal infection
    Medical condition: intraabdominal yeast infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004282-34 Sponsor Protocol Number: 2833 Start Date*: 2006-10-13
    Sponsor Name:Royal Marsden NHS Foundation Trust
    Full Title: A phase II study of bethanechol chloride to treat pseudomembranous candidosis in cancer patients with salivary gland dysfunction.
    Medical condition: Oral candidosis (pseudomembranous subtype)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2024-000582-24 Sponsor Protocol Number: V503-024 Start Date*: 2025-01-10
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity and Safety of 9-Valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine (V503) in Chinese females 9 to 45 Years of Age
    Medical condition: Papillomavirus Infections
    Disease: Version SOC Term Classification Code Term Level
    27.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2018-001269-18 Sponsor Protocol Number: VMT-VT-1161-CL-011 Start Date*: 2019-03-13
    Sponsor Name:Mycovia Pharmaceuticals, Inc
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects with Recurrent Vulvovaginal Candidiasis
    Medical condition: Recurrent Vulvovaginal Candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10047784 Vulvovaginal candidiasis PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: BG (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-000090-15 Sponsor Protocol Number: 213749 Start Date*: 2022-12-19
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase 1/2 randomized, observer-blinded, multi-country study to evaluate safety and immunogenicity of investigational adjuvanted human papillomavirus vaccine in females (16 to 26 years of age)
    Medical condition: Active immunisation for the prevention of human papillomavirus infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10071146 Human papilloma virus immunisation PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed) LT (Completed) FR (Completed) BG (Completed) EE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-004854-97 Sponsor Protocol Number: A8851019 Start Date*: 2008-01-15
    Sponsor Name:Pfizer Ltd
    Full Title: OPEN-LABEL, NON-COMPARATIVE, STUDY OF INTRAVENOUS ANIDULAFUNGIN, FOLLOWED OPTIONALLY BY ORAL VORICONAZOLE OR FLUCONAZOLE THERAPY, FOR TREATMENT OF DOCUMENTED CANDIDEMIA/INVASIVE CANDIDIASIS IN INTE...
    Medical condition: CANDIDAEMIA/INVASIVE CANDIDIASIS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064954 Invasive candidiasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) FR (Completed) BE (Completed) PT (Completed) NL (Completed) IT (Completed) SK (Completed) PL (Completed) CZ (Completed) DK (Completed) HU (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005278-11 Sponsor Protocol Number: A8851022 Start Date*: 2009-03-06
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: EFFICACY AND SAFETY OF ERAXIS™/ECALTA® (ANIDULAFUNGIN) COMPARED TO CANCIDAS® (CASPOFUNGIN) IN PATIENTS WITH CANDIDA DEEP TISSUE INFECTION
    Medical condition: INVASIVE CANDIDIA INFECTIONS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064954 Invasive candidiasis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) BE (Prematurely Ended) IE (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001270-26 Sponsor Protocol Number: VMT-VT-1161-CL-012 Start Date*: 2018-12-12
    Sponsor Name:Mycovia Pharmaceuticals, Inc
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects with Recurrent Vulvovaginal Candidiasis
    Medical condition: Recurrent Vulvovaginal Candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10047784 Vulvovaginal candidiasis PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: CZ (Completed) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-012848-16 Sponsor Protocol Number: A1501085 Start Date*: 2010-04-28
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
    Full Title: A PROSPECTIVE, OPEN-LABEL, NON-COMPARATIVE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF VORICONAZOLE FOR THE PRIMARY AND SALVAGE TREATMENT OF INVASIVE CANDIDIASIS, CANDIDEMIA, AND ESOPH...
    Medical condition: Invasive candidiasis, including candidemia (ICC), and esophageal candidiasis (EC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10060573 Candidemia LLT
    14.1 10021881 - Infections and infestations 10064954 Invasive candidiasis LLT
    14.1 10021881 - Infections and infestations 10007161 Candidiasis of the esophagus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) HU (Prematurely Ended) SK (Completed) CZ (Prematurely Ended) BG (Completed) RO (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-005277-35 Sponsor Protocol Number: A8851021 Start Date*: 2009-02-26
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: EFFICACY AND SAFETY OF ERAXIS™/ECALTA® (ANIDULAFUNGIN) COMPARED TO CANCIDAS® (CASPOFUNGIN) IN NEUTROPENIC PATIENTSWITH INVASIVE CANDIDA INFECTION
    Medical condition: INVASIVE CANDIDIA INFECTIONS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064954 Invasive candidiasis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) IE (Prematurely Ended) SK (Prematurely Ended) FR (Completed) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000780-24 Sponsor Protocol Number: 9463-CL-2303 Start Date*: 2012-07-24
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis
    Medical condition: Neonatal Candidiasis
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GR (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-004150-32 Sponsor Protocol Number: A8851008 Start Date*: 2008-11-18
    Sponsor Name:Pfizer, Spain
    Full Title: ESTUDIO PROSPECTIVO ABIERTO PARA EVALUAR LA FARMACOCINÉTICA, LA SEGURIDAD Y LA EFICACIA DE LA ANIDULAFUNGINA EN EL TRATAMIENTO DE NIÑOS Y ADOLESCENTES CON CANDIDIASIS INVASIVA, INCLUIDA LA CANDIDEM...
    Medical condition: CANDIDIASIS INVASIVA, INCLUIDA CANDIDEMIA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064954 Invasive candidiasis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) FR (Completed) PT (Completed) IT (Completed) GR (Completed) Outside EU/EEA GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003021-19 Sponsor Protocol Number: BCPP2005-01 Start Date*: 2006-08-22
    Sponsor Name:University Of Birmingham
    Full Title: The use of selenium and vitamin E supplementation to prevent recurrence and progression of non-muscle-invasive bladder cancer
    Medical condition: Non-muscle-invasive transitional cell carcinoma of the bladder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-001360-31 Sponsor Protocol Number: CKPV/21 Start Date*: 2005-07-04
    Sponsor Name:ABIOGEN PHARMA
    Full Title: A multicenter, randomised, double- blind, between-patient, dose finding study to assess the safety, tolerability and efficacy of three different dosages (500, 1000 and 2000 mcg/g) of ABIO 12/01 gel...
    Medical condition: VULVOVAGINAL CANDIDIASIS
    Disease: Version SOC Term Classification Code Term Level
    6.1 10046898 PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005707-92 Sponsor Protocol Number: 16-03/MicoFlu-C Start Date*: 2016-11-07
    Sponsor Name:Dermapharm AG
    Full Title: Double-blind, randomised clinical study comparing efficacy and safety of Miconazole 2% Fluprednidene 0.1% Cream (Test) vs. Vobaderm® Cream (Reference) vs. Vehicle in patients with moderate to sever...
    Medical condition: moderate to severely inflamed candidiasis of the skin
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10007159 Candidiasis of skin and nails LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003913-12 Sponsor Protocol Number: 22/589-EC_M. Start Date*: 2023-03-07
    Sponsor Name:COMPLUTENSE UNIVERSITY OF MADRID
    Full Title: Diode laser and photodynamic therapy Versus Ciclopirox Hydroxypropyl Chitosan. Randomised controlled clinical trial.
    Medical condition: Onychomycosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001010-42 Sponsor Protocol Number: 19-01/MicoFlu-C Start Date*: 2019-10-16
    Sponsor Name:Dermapharm AG
    Full Title: Double-blind, randomised clinical study comparing efficacy and safety of Miconazole 2%_Fluprednidene 0.1% Cream (Test) vs. Vobaderm® Cream (Reference) vs. Vehicle in patients with moderate to sever...
    Medical condition: moderate to severely inflamed candidiasis of the skin
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10007159 Candidiasis of skin and nails LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003790-65 Sponsor Protocol Number: 21-01/ClotriBet-S Start Date*: 2022-02-11
    Sponsor Name:Dermapharm AG
    Full Title: Double-blind, randomised clinical study comparing efficacy and safety of Mecloderm® Ointment (Test) vs. Lotricomb® Ointment (Reference) vs. Vehicle in patients with moderate to severely inflamed ca...
    Medical condition: moderate to severely inflamed candidiasis of the skin
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10007159 Candidiasis of skin and nails LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 19:19:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA